<scp>Eltrombopag</scp> Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority <scp>EBMT</scp> ‐ <scp>SAAWP RACE</scp> Study
Antonio M. Risitano(European Society for Blood and Marrow Transplantation), Ghulam J. Mufti(King's College London), Constantijn J.M. Halkes(Radboud University Nijmegen), Christian Récher(Institut universitaire du cancer de Toulouse Oncopole), Gèrard Socié(Hôpital Saint-Louis), Anna Maria Raiola(Ospedale Policlinico San Martino), Aline Praire(Centre Hospitalier Universitaire de Toulouse), Florence Rabian(Assistance Publique – Hôpitaux de Paris), Morag Griffin(Leeds Teaching Hospitals NHS Trust), Petra Muus(Radboud University Nijmegen), Fabiana Cacace(Duke University), Isabel Sánchez‐Ortega(European Society for Blood and Marrow Transplantation), Roochi Trikha(King's College Hospital NHS Foundation Trust), Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Nigel H. Russell(Guy's and St Thomas' NHS Foundation Trust), Marica Laurino(Hospices Civils de Lyon), Talha Munir(St James's University Hospital), Étienne Daguindau(Centre Hospitalier Universitaire de Besançon), Walter Barberi(Policlinico Umberto I), Austin Kulasekararaj(King's College London), Fiorenza Barraco(Hôpital Lyon Sud), Serena Marotta(Centre Hospitalier Universitaire de Toulouse), Erfan Nur(Sanquin), Isidro Jarque(Hospital Universitari i Politècnic La Fe), Louis Terriou(Centre Hospitalier Universitaire de Lille), Camilla Frieri(Université Paris Cité), Elena Palmisani(Istituto Giannina Gaslini), Jennifer M.L. Tjon(Leiden University Medical Center), Anna Paola Iori(Sapienza University of Rome), Blanca Xicoy(Hospital Universitari Germans Trias i Pujol), Shreyans Gandhi(King's College Hospital), Marco R. de Groot(University Medical Center Groningen), Simona Iacobelli(European Society for Blood and Marrow Transplantation), Brian Piepenbroek(Leiden University), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Flore Sicre de Fontbrune(Assistance Publique – Hôpitaux de Paris), Laura G.M. Daenen(Utrecht University), Marleen van Os(Universität Hamburg), Beatrice Drexler(University Hospital of Basel), Édouard Forcade(Hôpital Cardiologique du Haut-Lévêque), Suzanne Tavitian(Institut universitaire du cancer de Toulouse Oncopole), Joe Tuffnell(European Society for Blood and Marrow Transplantation), Carlos Vallejo(Universidad de Salamanca), Laurence Clément(Centre Hospitalier Universitaire de Bordeaux), Anita Hill(Leeds General Infirmary), Jean‐Baptiste Mear(Université Rennes 2), James Cavenagh(St Bartholomew's Hospital), Luana Marano(Centre Hospitalier Universitaire de Toulouse), Sofie R. Terwel(European Society for Blood and Marrow Transplantation), Jakob Passweg(University Hospital of Basel)
Cited by 0
Related Papers
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
|Nature|2010|1.3k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k